This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
31 Aug 2011

Helsinn Enrols First Patient in Phase III Cancer Drug Trial

The primary efficacy endpoints include a measure of difference in the change in lean body mass and muscle strength in patients with weight loss associated with non-small cell lung cancer.

Swiss-based pharmaceutical company Helsinn Therapeutics has enrolled its first patient in a Phase III clinical programme evaluating Anamorelin HCl as a treatment of anorexia and cachexia in patients with advanced non-small cell lung cancer.

 

The two randomised, double-blind, placebo controlled, multicentre and global Phase III studies – Romana-1 and Romana-2 – are expected to enrol up to 477 patients each. The primary efficacy endpoints include a measure of difference in the change in lean body mass and muscle strength in patients with weight loss associated with non-small cell lung cancer.

 

Pharmacokinetic and additional safety measures will also be evaluated in the trials.

 

Anamorelin HCl is an orally ad

Related News